Test will 'revolutionise' cancer treatment
Thursday 31 May 2012
Cancer diagnosis and treatment could be "revolutionised" by a new low-cost blood test which allows doctors to track genetic changes in tumour cells.
The "liquid biopsy" test identifies defective fragments of DNA shed into the bloodstream by cancer cells as they die.
Scientists have already used it to detect genetic faults involved in tumour growth in blood samples from 20 women with ovarian cancer. They were also able to build a "real time" picture of how one woman's breast cancer responded to treatment over more than a year.
Study leader Dr Nitzan Rosenfeld, from Cancer Research UK's Cambridge Research Institute, said: "This type of blood test has the potential to revolutionise the way we diagnose and treat cancer. The great advantage is that it can be used to identify cancer mutations without surgery or a biopsy, making it safer and cheaper."
In future, patients could be given treatments based on the result of a quick blood test, rather than having a tissue sample surgically removed for analysis.
The test is said to overcome a major drawback of tumour biopsies, which may provide only a limited snapshot of the genetic mutations present in cancer.
Diving in at the deep end is no excuse for shirking the style stakes
Life & Style blogs
- 1 Stephen Fry ‘criticises Operation Yewtree in dinner party rant’ calling for tougher laws to deter false sex abuse allegations
- 2 Belgium fan Axelle Despiegelaere lands L'Oreal campaign after World Cup viral photo
- 3 Why I'm on the brink of burning my Israeli passport
- 4 Israel-Gaza conflict: ‘Sderot cinema’ image shows Israelis with popcorn and chairs 'cheering as missiles strike Palestinian targets'
- 5 Blackest is the new black: Scientists have developed a material so dark that you can't see it...
£40000 - £60000 per annum + Benefits + Bonus: Harrington Starr: Dynamics CRM D...
£40000 - £45000 per annum + Benefits + Bonus: Harrington Starr: Web Developer ...
£50000 - £67000 per annum + Benefits + Bonus: Harrington Starr: C# R&D .NE...
£40000 - £50000 per annum + Benefits + Bonus: Harrington Starr: C# Developer (...